CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Top Cited Papers
Open Access
- 12 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (10), 1797-1805
- https://doi.org/10.1038/s41591-021-01497-1
Abstract
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potentially prevent this, but the clinical safety and efficacy of CAR T cells targeting both CD19 and CD22 remain unclear. We conducted a phase 1 trial in pediatric and young adult patients with relapsed or refractory B-ALL (n = 15) to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 CARs (AMELIA trial, EUDRA CT 2016-004680-39). The primary endpoints were the incidence of grade 3–5 toxicity in the dose-limiting toxicity period and the frequency of dose-limiting toxicities. Secondary endpoints included the rate of morphological remission (complete response or complete response with incomplete bone marrow recovery) with minimal residual disease-negative response, as well as the frequency and severity of adverse events, expansion and persistence of AUTO3, duration of B cell aplasia, and overall and event-free survival. The study endpoints were met. AUTO3 showed a favorable safety profile, with no dose-limiting toxicities or cases of AUTO3-related severe cytokine release syndrome or neurotoxicity reported. At 1 month after treatment the remission rate (that is, complete response or complete response with incomplete bone marrow recovery) was 86% (13 of 15 patients). The 1 year overall and event-free survival rates were 60% and 32%, respectively. Relapses were probably due to limited long-term AUTO3 persistence. Strategies to improve CAR T cell persistence are needed to fully realize the potential of dual targeting CAR T cell therapy in B-ALL.Keywords
Funding Information
- Autolus Therapeutics plc
This publication has 30 references indexed in Scilit:
- Antibody structure determination using a combination of homology modeling, energy‐based refinement, and loop predictionProteins, 2014
- HLA Class I Alleles Are Associated with Peptide-Binding Repertoires of Different Size, Affinity, and ImmunogenicityThe Journal of Immunology, 2013
- Monoclonal antibody humanness score and its applicationsBMC Biotechnology, 2013
- Paths to stemness: building the ultimate antitumour T cellNature Reviews Cancer, 2012
- Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six DesignJournal of Clinical Oncology, 2008
- The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cellsBlood, 2005
- Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia, 2004
- Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ ChainThe Journal of Immunology, 2004
- Interpreting Kinetic Rate Constants from Optical Biosensor Data Recorded on a Decaying SurfaceAnalytical Biochemistry, 1998
- HD37 Monoclonal Antibody: A Useful Reagent for Further Characterization of “Non-T, Non-B” Lymphoid MalignanciesPublished by Springer Science and Business Media LLC ,1986